XML 25 R7.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury
Noncontrolling Interests
Beginning balance, common stock (in shares) at Mar. 31, 2022   275          
Beginning balance, treasury common stock (shares) at Mar. 31, 2022           (130)  
Beginning balance at Mar. 31, 2022 $ (1,792) $ 2 $ 7,275 $ 9,030 $ (1,534) $ (17,045) $ 480
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of shares under employee plans, net of forfeitures (in shares)   2          
Issuance of shares under employee plans, net of forfeitures 4 $ 1 163     $ (160)  
Share-based compensation 161   161        
Repurchase of common stock (in shares)           (11)  
Repurchase of common stock (3,665)   127     $ (3,792)  
Net income 3,722     3,560     162
Other comprehensive income (loss) 673       629   44
Cash dividends declared (296)     (296)      
Payments to noncontrolling interests (150)           (150)
Reclassification of recurring compensation to other accrued liabilities (5)           (5)
Formation of SCRI Oncology 247   22       225
Derecognition of noncontrolling interests in McKesson Europe (382)           (382)
Other (7)   (1) 1     (7)
Ending balance common stock (in shares) at Mar. 31, 2023   277          
Ending balance, treasury common stock (shares) at Mar. 31, 2023           (141)  
Ending balance at Mar. 31, 2023 (1,490) $ 3 7,747 12,295 (905) $ (20,997) 367
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of shares under employee plans, net of forfeitures (in shares)   1          
Issuance of shares under employee plans, net of forfeitures 17   116     $ (99)  
Share-based compensation 182   182        
Repurchase of common stock (in shares)           (7)  
Repurchase of common stock (3,023)         $ (3,023)  
Net income 3,160     3,002     158
Other comprehensive income (loss) 24       24    
Cash dividends declared (320)     (320)      
Payments to noncontrolling interests (152)           (152)
Other 3   3 1     (1)
Ending balance common stock (in shares) at Mar. 31, 2024   278          
Ending balance, treasury common stock (shares) at Mar. 31, 2024           (148)  
Ending balance at Mar. 31, 2024 (1,599) $ 3 8,048 14,978 (881) $ (24,119) 372
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of shares under employee plans, net of forfeitures (in shares)   1          
Issuance of shares under employee plans, net of forfeitures (47)   101     $ (148)  
Share-based compensation 226   226        
Repurchase of common stock (in shares)           (6)  
Repurchase of common stock (3,172)         $ (3,172)  
Net income 3,481     3,295     186
Other comprehensive income (loss) (51)       (51)    
Cash dividends declared (352)     (352)      
Payments to noncontrolling interests (178)           (178)
Other (2)   (2) 0     0
Ending balance common stock (in shares) at Mar. 31, 2025   279          
Ending balance, treasury common stock (shares) at Mar. 31, 2025           (154)  
Ending balance at Mar. 31, 2025 $ (1,694) $ 3 $ 8,373 $ 17,921 $ (932) $ (27,439) $ 380